Another clinical study reported that treatment with low-dose combinations of two FDA-approved epidrugs, azacytidine (A) and romidepsin (R), along with IFNα2 (ARI) hampers the aggressiveness of colorectal carcinoma cells and cancer stem cells in vivo and triggers tumor cell ICD that in turn, stimulates DC function [230]. This evidence concerns the gene IFNA2 and neoplasm.